Barr Tamoxifen Sales Benefit From Zeneca's Risk Reduction Campaign

Barr's tamoxifen sales increased by more than one-third in the third quarter of fiscal 1999, Barr CEO Bruce Downey said during an April 21 conference call.

More from Archive

More from Pink Sheet